{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:44:11Z","timestamp":1793295851738,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82300096"],"award-info":[{"award-number":["82300096"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82270079"],"award-info":[{"award-number":["82270079"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-19460-2","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T09:32:01Z","timestamp":1760088721000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Prognostic risk factors and a survival prediction model for immune checkpoint inhibitor related myocarditis in patients with lung cancer: a multicenter study"],"prefix":"10.1038","volume":"15","author":[{"given":"Xiaoyun","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingzhi","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoliang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"key":"19460_CR1","doi-asserted-by":"publisher","first-page":"3797","DOI":"10.1038\/s41467-025-59092-8","volume":"16","author":"W Pan","year":"2025","unstructured":"Pan, W. et al. Identification of predictive subphenotypes for clinical outcomes using real world data and machine learning. Nat. Commun. 16, 3797. https:\/\/doi.org\/10.1038\/s41467-025-59092-8 (2025).","journal-title":"Nat. Commun."},{"key":"19460_CR2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.0985","author":"J Heyward","year":"2025","unstructured":"Heyward, J., Lesko, C. R., Murray, J. C., Mehta, H. B. & Segal, J. B. Harm-Benefit balance of immune checkpoint inhibitors in Non-Small cell lung cancer. JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2025.0985 (2025).","journal-title":"JAMA Oncol."},{"key":"19460_CR3","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jaccao.2025.01.020","volume":"7","author":"YC Chen","year":"2025","unstructured":"Chen, Y. C. et al. Immune checkpoint inhibitor myocarditis and left ventricular systolic dysfunction. JACC CardioOncology. 7, 234\u2013248. https:\/\/doi.org\/10.1016\/j.jaccao.2025.01.020 (2025).","journal-title":"JACC CardioOncology"},{"key":"19460_CR4","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"SS Mahmood","year":"2018","unstructured":"Mahmood, S. S. et al. Myocarditis in patients treated with immune checkpoint inhibitors. J. Am. Coll. Cardiol. 71, 1755\u20131764. https:\/\/doi.org\/10.1016\/j.jacc.2018.02.037 (2018).","journal-title":"J. Am. Coll. Cardiol."},{"key":"19460_CR5","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson, D. B. et al. Fulminant myocarditis with combination immune checkpoint Blockade. N. Engl. J. Med. 375, 1749\u20131755. https:\/\/doi.org\/10.1056\/NEJMoa1609214 (2016).","journal-title":"N. Engl. J. Med."},{"key":"19460_CR6","doi-asserted-by":"publisher","unstructured":"Moslehi, J., Lichtman, A. H., Sharpe, A. H., Galluzzi, L. & Kitsis, R. N. Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms. J. Clin. Investig. 131 https:\/\/doi.org\/10.1172\/jci145186 (2021).","DOI":"10.1172\/jci145186"},{"key":"19460_CR7","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/s1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"Salem, J. E. et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 19, 1579\u20131589. https:\/\/doi.org\/10.1016\/s1470-2045(18)30608-9 (2018).","journal-title":"Lancet Oncol."},{"key":"19460_CR8","doi-asserted-by":"publisher","first-page":"879900","DOI":"10.3389\/fimmu.2022.879900","volume":"13","author":"X Xie","year":"2022","unstructured":"Xie, X. et al. Multi-organ immune-Related adverse event is a risk factor of immune checkpoint Inhibitor-Associated myocarditis in cancer patients: A Multi-center study. Front. Immunol. 13, 879900. https:\/\/doi.org\/10.3389\/fimmu.2022.879900 (2022).","journal-title":"Front. Immunol."},{"key":"19460_CR9","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1002\/ejhf.3340","volume":"26","author":"CG Tocchetti","year":"2024","unstructured":"Tocchetti, C. G. et al. Cardiovascular toxicities of immune therapies for cancer - a scientific statement of the heart failure association (HFA) of the ESC and the ESC Council of Cardio-Oncology. Eur. J. Heart Fail. 26, 2055\u20132076. https:\/\/doi.org\/10.1002\/ejhf.3340 (2024).","journal-title":"Eur. J. Heart Fail."},{"key":"19460_CR10","doi-asserted-by":"publisher","first-page":"e007524","DOI":"10.1161\/circheartfailure.120.007524","volume":"14","author":"GT Giblin","year":"2021","unstructured":"Giblin, G. T. et al. Subclinical myocarditis after combination immune checkpoint inhibitor therapy. Circ. Heart. Fail. 14, e007524. https:\/\/doi.org\/10.1161\/circheartfailure.120.007524 (2021).","journal-title":"Circ. Heart. Fail."},{"key":"19460_CR11","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1161\/circulationaha.120.052307","volume":"143","author":"BL Bermas","year":"2021","unstructured":"Bermas, B. L. & Zaha, V. G. Mending broken hearts: A new treatment paradigm for immune checkpoint Inhibitor-Induced myocarditis. Circulation 143, 767\u2013769. https:\/\/doi.org\/10.1161\/circulationaha.120.052307 (2021).","journal-title":"Circulation"},{"key":"19460_CR12","doi-asserted-by":"publisher","unstructured":"S\u0142awi\u0144ski, G., Wrona, A., D\u0105browska-Kugacka, A., Raczak, G. & Lewicka, E. Immune checkpoint inhibitors and cardiac toxicity in patients treated for Non-Small lung cancer: A review. Int. J. Mol. Sci. 21 https:\/\/doi.org\/10.3390\/ijms21197195 (2020).","DOI":"10.3390\/ijms21197195"},{"key":"19460_CR13","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","volume":"43","author":"J Herrmann","year":"2022","unstructured":"Herrmann, J. et al. Defining cardiovascular toxicities of cancer therapies: an international Cardio-Oncology society (IC-OS) consensus statement. Eur. Heart J. 43, 280\u2013299. https:\/\/doi.org\/10.1093\/eurheartj\/ehab674 (2022).","journal-title":"Eur. Heart J."},{"key":"19460_CR14","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1161\/circulationaha.118.034497","volume":"140","author":"MP Bonaca","year":"2019","unstructured":"Bonaca, M. P. et al. Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in Cardio-Oncology. Circulation 140, 80\u201391. https:\/\/doi.org\/10.1161\/circulationaha.118.034497 (2019).","journal-title":"Circulation"},{"key":"19460_CR15","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1161\/cir.0000000000000156","volume":"132","author":"KA Hicks","year":"2015","unstructured":"Hicks, K. A. et al. 2014 ACC\/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: A report of the American college of cardiology\/american heart association task force on clinical data standards (Writing committee to develop cardiovascular endpoints data standards). Circulation 132, 302\u2013361. https:\/\/doi.org\/10.1161\/cir.0000000000000156 (2015).","journal-title":"Circulation"},{"key":"19460_CR16","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/jco.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider, B. J. et al. Management of immune-Related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J. Clin. Oncology: Official J. Am. Soc. Clin. Oncol. 39, 4073\u20134126. https:\/\/doi.org\/10.1200\/jco.21.01440 (2021).","journal-title":"J. Clin. Oncology: Official J. Am. Soc. Clin. Oncol."},{"key":"19460_CR17","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1001\/jama.1994.03510400062033","volume":"271","author":"WH Gaasch","year":"1994","unstructured":"Gaasch, W. H. Diagnosis and treatment of heart failure based on left ventricular systolic or diastolic dysfunction. Jama 271, 1276\u20131280 (1994).","journal-title":"Jama"},{"key":"19460_CR18","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang, D. Y. et al. Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and Meta-analysis. JAMA Oncol. 4, 1721\u20131728. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3923 (2018).","journal-title":"JAMA Oncol."},{"key":"19460_CR19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.6515\/acs.202201_38(1).20210830b","volume":"38","author":"NC Wu","year":"2022","unstructured":"Wu, N. C. et al. Clinical features and outcomes of immune checkpoint Inhibitor-Associated cardiovascular toxicities. Acta Cardiol. Sinica. 38, 39\u201346. https:\/\/doi.org\/10.6515\/acs.202201_38(1).20210830b (2022).","journal-title":"Acta Cardiol. Sinica"},{"key":"19460_CR20","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.acvd.2022.03.003","volume":"115","author":"JR Power","year":"2022","unstructured":"Power, J. R. et al. Association of early electrical changes with cardiovascular outcomes in immune checkpoint inhibitor myocarditis. Arch. Cardiovasc. Dis. 115, 315\u2013330. https:\/\/doi.org\/10.1016\/j.acvd.2022.03.003 (2022).","journal-title":"Arch. Cardiovasc. Dis."},{"key":"19460_CR21","doi-asserted-by":"publisher","first-page":"e70154","DOI":"10.1002\/clc.70154","volume":"48","author":"G Alexander","year":"2025","unstructured":"Alexander, G. et al. Immune checkpoint Inhibitor-Related myocarditis: A single center observational registry. Clin. Cardiol. 48, e70154. https:\/\/doi.org\/10.1002\/clc.70154 (2025).","journal-title":"Clin. Cardiol."},{"key":"19460_CR22","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/s0140-6736(18)30533-6","volume":"391","author":"JJ Moslehi","year":"2018","unstructured":"Moslehi, J. J., Salem, J. E., Sosman, J. A., Lebrun-Vignes, B. & Johnson, D. B. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet (London England). 391, 933. https:\/\/doi.org\/10.1016\/s0140-6736(18)30533-6 (2018).","journal-title":"Lancet (London England)"},{"key":"19460_CR23","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1007\/s00432-019-02927-x","volume":"145","author":"SA Atallah-Yunes","year":"2019","unstructured":"Atallah-Yunes, S. A., Kadado, A. J., Kaufman, G. P. & Hernandez-Montfort, J. Immune checkpoint inhibitor therapy and myocarditis: a systematic review of reported cases. J. Cancer Res. Clin. Oncol. 145, 1527\u20131557. https:\/\/doi.org\/10.1007\/s00432-019-02927-x (2019).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"19460_CR24","doi-asserted-by":"publisher","first-page":"e753","DOI":"10.1634\/theoncologist.2019-0666","volume":"25","author":"S Khan","year":"2020","unstructured":"Khan, S. et al. Late-Onset immunotherapy toxicity and delayed autoantibody changes: checkpoint Inhibitor-Induced Raynaud\u2019s-Like phenomenon. Oncologist 25, e753\u2013e757. https:\/\/doi.org\/10.1634\/theOncologist.2019-0666 (2020).","journal-title":"Oncologist"},{"key":"19460_CR25","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41379-019-0363-0","volume":"33","author":"SN Champion","year":"2020","unstructured":"Champion, S. N. & Stone, J. R. Immune checkpoint inhibitor associated myocarditis occurs in both high-grade and low-grade forms. Mod. Pathology: Official J. United States Can. Acad. Pathol. Inc. 33, 99\u2013108. https:\/\/doi.org\/10.1038\/s41379-019-0363-0 (2020).","journal-title":"Mod. Pathology: Official J. United States Can. Acad. Pathol. Inc"},{"key":"19460_CR26","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1161\/circulationaha.119.044703","volume":"141","author":"L Zhang","year":"2020","unstructured":"Zhang, L. et al. Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint Inhibitor-Associated myocarditis. Circulation 141, 2031\u20132034. https:\/\/doi.org\/10.1161\/circulationaha.119.044703 (2020).","journal-title":"Circulation"},{"key":"19460_CR27","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s10147-020-01666-1","volume":"25","author":"H Sato","year":"2020","unstructured":"Sato, H., Okonogi, N. & Nakano, T. Rationale of combination of anti-PD-1\/PD-L1 antibody therapy and radiotherapy for cancer treatment. Int. J. Clin. Oncol. 25, 801\u2013809. https:\/\/doi.org\/10.1007\/s10147-020-01666-1 (2020).","journal-title":"Int. J. Clin. Oncol."},{"key":"19460_CR28","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/j.annonc.2020.09.016","volume":"31","author":"N Shaverdian","year":"2020","unstructured":"Shaverdian, N. et al. Safety of thoracic radiotherapy in patients with prior immune-related adverse events from immune checkpoint inhibitors. Annals Oncology: Official J. Eur. Soc. Med. Oncol. 31, 1719\u20131724. https:\/\/doi.org\/10.1016\/j.annonc.2020.09.016 (2020).","journal-title":"Annals Oncology: Official J. Eur. Soc. Med. Oncol."},{"key":"19460_CR29","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1200\/jco.2007.10.9777","volume":"25","author":"JR Carver","year":"2007","unstructured":"Carver, J. R. et al. American society of clinical oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J. Clin. Oncology: Official J. Am. Soc. Clin. Oncol. 25, 3991\u20134008. https:\/\/doi.org\/10.1200\/jco.2007.10.9777 (2007).","journal-title":"J. Clin. Oncology: Official J. Am. Soc. Clin. Oncol."},{"key":"19460_CR30","doi-asserted-by":"publisher","first-page":"1025455","DOI":"10.3389\/fonc.2022.1025455","volume":"12","author":"C Son","year":"2022","unstructured":"Son, C. et al. Cardiac toxicity in patients with lung cancer receiving thoracic radiotherapy and immunotherapy. Front. Oncol. 12, 1025455. https:\/\/doi.org\/10.3389\/fonc.2022.1025455 (2022).","journal-title":"Front. Oncol."},{"key":"19460_CR31","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1158\/0008-5472.Can-14-3511","volume":"75","author":"C Vanpouille-Box","year":"2015","unstructured":"Vanpouille-Box, C. et al. TGF\u03b2 is a master regulator of radiation Therapy-Induced antitumor immunity. Cancer Res. 75, 2232\u20132242. https:\/\/doi.org\/10.1158\/0008-5472.Can-14-3511 (2015).","journal-title":"Cancer Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19460-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19460-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19460-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T09:32:04Z","timestamp":1760088724000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19460-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["19460"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-19460-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]},"assertion":[{"value":"22 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This research was approved by the Medical Ethics Committee of Xiangya Hospital of Central South University (NO.202212310). All participants gave their informed consent for inclusion before they participated in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}],"article-number":"35514"}}